Influence of deproteinized hemodialysate on rest pain and walking distance in the presence of peripheral chronic arterial occlusive disease.
In a controlled and randomized single-blind study (blind observer) the clinical efficacy of intra-arterial therapy with a metabolically active deproteinized dialysate from calf blood has been tested against a vasodilating and hemorheologically active reference substance (bencyclan). Over a period of four weeks 28 patients each received 20 intra-arterial infusions of the deproteinized hemodialysate 20% for infusion. The reference group with 30 patients was treated with 250 mg bencyclan in 250 mL saline 0.9%. As for the target criteria, rest pain and consumption of analgesics, the hemodialysate treatment proved superior to the therapy with the reference substance. Both preparations induced to a small extent pain-free walking distances: hemodialysate group, 29.2 +/- 14.6 m; reference group, 25.8 +/- 18.7 m (group difference not significant).
Angelkort
B
B
Department of Central Medicine, Municipal Hospital, Dortmund, Germany.
Rühlmann
K U
KU
de la Haye
R
R
Kuntz
G
G
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D001537:Bencyclane / Q000008:administration & dosage; D001685:Biological Factors / Q000008:administration & dosage*; D001798:Blood Proteins / Q000302:isolation & purification; D002417:Cattle; D002908:Chronic Disease; D006801:Humans; D007261:Infusions, Intra-Arterial; D059408:Pain Management; D006435:Renal Dialysis; D012146:Rest; D016037:Single-Blind Method; D013997:Time Factors; D016138:Walking
D001685:Biological Factors; D001798:Blood Proteins; D001537:Bencyclane